

Jointly Provided by Saint Peter's University Hospital and Rutgers Biomedical and Health Sciences

https://SaintPetersHCS.zoom.us/webinar/register/WN_JgV2w_BiT7igOI-OBIF5XA

Tuesday, September 28, 2021

12:00 PM to 1:00 PM

“Alcohol Related Liver Disease in 2021: An Update”



Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP (Edin)
Professor and Chief,
Division of Gastroenterology and Hepatology
Professor, Physiology, Pharmacology and Neuroscience
Medical Director Liver Transplantation
Rutgers Robert Wood Johnson Medical School
University Hospital

Objectives

At the conclusion of this activity, participants should be better able to:

- Summarize the conditions and factors that aggravate the Alcohol associated liver disease
- Identify current laboratory testing recommendations for Alcohol associated liver disease
- Describe recent advances in the drug treatment of Alcohol associated liver disease

Target Audience: This activity is designed for internists, advanced practice nurses, physician assistants, pharmacists, nurses, fellows, residents, and medical students.

Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and Saint Peter's University Hospital. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCM), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is awarded 1 contact hours. (60 minute CH)

Pharmacists: This knowledge-based activity qualifies for 1 contact hours (1 CEUs) of continuing pharmacy education credit.

Disclosure Declarations

Dr. Pyrsopoulos has the following relevant financial relationships with ineligible companies: Consulting Fee: BEIGENE; Grant/Research Support: DURECT, GRIFOLS, ABBVIE, BEIGENE, PROMETHEUS, GENFIT, INTERCEPT, SALIX, BAYER
All of the relevant financial relationships listed have been mitigated.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee:

Drs. Nayan Kothari (Activity Director/Content Reviewer), Kim Dixon (Content Reviewer), Janani Mohan, Mehak Bassi, Joan Lynn, APN, Avni Desai, PharmD, and Daria Colbert-Carter have no relevant financial relationships with ineligible companies to disclose.